Neosil (Nimesulide) №20 TabNon-steroidal anti-inflammatory agent
ATС Code: M01AX17.  

Drug form: Pills.

Composition: Active substance: Nimesulide - 100 mg.

Aiding substances: starch, micromeritic cellulose, sorbite, talc, calcium or magnesium stearate, polyvinylpyrrolidone.

Pharmacological operation:

Neosili is an anti inflammatory nonsteroidal mean form the Sulfonanilid group. Is characterizes with anti inflammation, painkilling and temperature lowering action, that is caused by selective competitive inhibition of the enzyme cyclooxygenase – 2; it suppresses prostaglandins – intumescence, inflammation and pain mediation synthesis. Besides that, the preparation suppresses synthesis of cartilaginous tissue’s disbanding enzyme (Colagenesis, Stromelizin, Elastaza), which delays cartilaginous tissue’s damage and subserves regulation of this system.

After internal taking, Nimesulid is absorbed well from intestine tract. Ingest of food reduces absorption speed, irreplaceable to absorbing quality. Nimesulid’s maximal concentration in blood plasma is achieved after 1,5 -2,5 hours taking, but its operation  continues approximately 6 hours. 99% of Nimesulid relates to plasma proteins, actively metabolizes in liver, 80 % of metabolite is exiled by means of urine, but 20% - together with  fecal mass.

Indication:

·      At time of joint and muscles diseases (different genesis osteoarthritis, among them rheumatic gout, osteoarthrosis, ankylosing spondylitis, bursitis, tendenitis);

·      For pain alleviation at post operational and posttraumatic period, at time of osteoarthritis, strain and dislocation pains and for inflammation treatment (arthralgia, myalgia);

·      At time of infectious - inflammatory diseases in otolaryngology;

·      At time of teeth and headache, also dysmenorrheal (at time of painful menstruation);

·      At time of fever current diseases (like involving in combined therapy).

Contra-indication: High sensitivity towards the Nimesulide and other components of the preparation; high sensitivity towards acetylsalicylic acid or other anti-inflammatory nonsteroidalm means; stomach and duodenum ulcerous diseases in an acute phase; normal or expressed disorders of the liver or kidney function; pregnancy and lactation period; for children – till 12 age;

Using rule and dosage: Neosili is taken perorally, after eating, drinking plenty of fluids.

It is commonly prescribed – 100mg (1 tablet) 2 times in a day. Given the state of the patient, and the effectiveness of treatment dose can be increased to 200 mg two times a day.

In aged people choose and reduce of doses is determined by the doctor according to the patient’s condition.

For children up to 12 year Neosili is only prescribed by the doctor’s recommendation.

Taking the drug recommended as possible in a short time, for whatever cvesti minimize the risk of side effects (for not more than 15 days).

Side effects: Neosili is characterized with good endurance, although there may be developed:

From the side of gastrointestinal tract: discomfort of epigastrium, nausea and diarrhea;

From the side of central nervous system: headache, insomnia, nausia.

Alergic  reactions: rash on the skin, erythema, hives, itch;

Rarely there may be developed  oliguria with liquid retain and local or diffuse intumescence of the tissue.

Like other anti-inflammatory nonsteroidal means Neosili may cause Steven  Johnson’s, Layel’s syndrome, also anaphylactic reactions.

In case of side-effects  occurance  shoul get  consultation from  doctor and stop taking the preparation.

Safety measures: Neosili if safely prescribed for those patients who have blood coagulation system disorder and intestine system diseases, also patients who take anticoagulants or antiaggregant. Patients who have kidney’s functional disorder have to reduce dosage of Nimesulide with consideration of hanking filtration indicator.

The preparation may cause liquid retain in the tissues, so, Nimesulide should be given safely to those patients who have heart insufficiency.

 Neosil if safely given to aged patients, especially when there is expressed age weakness.

It is necessary to be safely at time of prescribing Neosil and anticoagulants, diuresis means, antihypertensive preparations, hypoglycemic preparations, digoxin, phenytoin, lithium preparations and other nonsteroidal anti-inflammatory means, cyclosporine and methotrexate simultaneously.

Overdose: In case of overdosage following symptoms may be occurred: nausea, vomiting, insomnia. Treatment is symptomatic, stomach ablution and  taking of activated carbon is recommended.    

Pregnancy and lactation period: Usage of Neosili is not recommended during the period of pregnancy and lactation.

Influence on ability of management of motor transport and mechanisms: Caution should be taken because the preparation may cause sleepness and dizziness.

Interactions with other drugs: Caution should be exercised with concomitant administration of Neosili and anticoagulants, diuretics, antihypertensive drugs, hypoglycemic drugs, digoxin, phenytoin, lithium, other non-steroidal anti-inflammatory drugs, cyclosporine, methotrexate, as there may be the case they interact.

Package: Primary packing: № 10 tablets in polyvinylchloride blister. Secondary packing: 2 blisters are located in a cardboard box.

Storage conditions: Store on 15-25ºC temperature in a dark, dry place and keep away from children.

Validity: 2 years.

Issue: II group of a pharmaceutical product, issued with prescription №3.